{"nctId":"NCT04518410","briefTitle":"ACTIV-2: A Study for Outpatients With COVID-19","startDateStruct":{"date":"2020-08-19","type":"ACTUAL"},"conditions":["Coronavirus","Covid19"],"count":4044,"armGroups":[{"label":"Bamlanivimab 7000 mg (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: bamlanivimab 7000mg"]},{"label":"Bamlanivimab 7000mg Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for Bamlanivimab 7000mg"]},{"label":"Bamlanivimab 700mg (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: bamlanivimab 700mg"]},{"label":"Bamlanivimab 700mg Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for Bamlanivimab 700mg"]},{"label":"Bamlanivimab 700mg (Phase 3)","type":"EXPERIMENTAL","interventionNames":["Biological: bamlanivimab 700mg"]},{"label":"BRII-196+BRII-198 (Pooled Phase 2/3)","type":"EXPERIMENTAL","interventionNames":["Biological: BRII-196+BRII-198"]},{"label":"BRII-196+BRII-198 Placebo (Pooled Phase 2/3)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for BRII-196+BRII-198"]},{"label":"AZD7442 (IV) (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: AZD7442 (IV)"]},{"label":"AZD7442 (IV) Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for AZD7442 (IV)"]},{"label":"AZD7442 (IM) (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: AZD7442 (IM)"]},{"label":"AZD7442 (IM) Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for AZD7442 (IM)"]},{"label":"SNG001 (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Drug: SNG001"]},{"label":"SNG001 Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for SNG001"]},{"label":"Camostat (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Camostat"]},{"label":"Camostat Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for Camostat"]},{"label":"SAB-185 (low dose) (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: SAB-185 (3,840 Units/kg)"]},{"label":"SAB-185 (low dose) Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for SAB-185 (low dose)"]},{"label":"SAB-185 (low dose) (Phase 3) Non-OMICRON population","type":"EXPERIMENTAL","interventionNames":["Biological: SAB-185 (3,840 Units/kg)"]},{"label":"Casirivimab and Imdevimab (Phase 3) Non-OMICRON population","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: CASIRIVIMAB + IMDEVIMAB"]},{"label":"SAB-185 (high dose) (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: SAB-185 (10,240 Units/kg)"]},{"label":"SAB-185 (high dose) Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for SAB-185 (high dose)"]},{"label":"BMS 986414+BMS 986413 (Phase 2)","type":"EXPERIMENTAL","interventionNames":["Biological: BMS-986414 + BMS-986413"]},{"label":"BMS 986414+BMS 986413 Pooled Placebo (Phase 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo for BMS-986414 + BMS-986413"]},{"label":"SAB-185 (low dose) (Phase 3) OMICRON population","type":"EXPERIMENTAL","interventionNames":["Biological: SAB-185 (3,840 Units/kg)"]},{"label":"Casirivimab and Imdevimab (Phase 3) OMICRON population","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: CASIRIVIMAB + IMDEVIMAB"]}],"interventions":[{"name":"bamlanivimab 7000mg","otherNames":["LY3819253"]},{"name":"BRII-196+BRII-198","otherNames":[]},{"name":"AZD7442 (IV)","otherNames":["AZD8895 + AZD1061"]},{"name":"AZD7442 (IM)","otherNames":["AZD8895 + AZD1061"]},{"name":"SNG001","otherNames":[]},{"name":"Camostat","otherNames":["FOY-305","camostat mesilate","camostat mesylate"]},{"name":"BMS-986414 + BMS-986413","otherNames":["C135-LS + C144-LS"]},{"name":"SAB-185 (3,840 Units/kg)","otherNames":["Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived)"]},{"name":"SAB-185 (10,240 Units/kg)","otherNames":["Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived)"]},{"name":"CASIRIVIMAB + IMDEVIMAB","otherNames":["REGN10933 + REGN10987","REGN-COV2"]},{"name":"Placebo for Bamlanivimab 7000mg","otherNames":[]},{"name":"Placebo for Bamlanivimab 700mg","otherNames":[]},{"name":"Placebo for BRII-196+BRII-198","otherNames":[]},{"name":"Placebo for SNG001","otherNames":[]},{"name":"Placebo for Camostat","otherNames":[]},{"name":"Placebo for SAB-185 (low dose)","otherNames":[]},{"name":"Placebo for BMS-986414 + BMS-986413","otherNames":[]},{"name":"Placebo for AZD7442 (IV)","otherNames":[]},{"name":"Placebo for AZD7442 (IM)","otherNames":[]},{"name":"Placebo for SAB-185 (high dose)","otherNames":[]},{"name":"bamlanivimab 700mg","otherNames":["LY3819253"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent.\n* Documentation of laboratory-confirmed SARS-CoV-2 infection, as determined by a molecular (nucleic acid) or antigen test from any respiratory tract specimen (e.g. oropharyngeal, nasopharyngeal (NP), or nasal swab, or saliva) collected ≤240 hours (10 days) prior to study entry. Laboratory-confirmed SARS-CoV-2 infection outside the US must be conducted at a DAIDS-approved laboratory.\n* Able to begin study treatment no later than 7 days from self-reported onset of COVID-19 related symptom(s) or measured fever, where the first day of symptoms is considered symptom day 0 and defined by the self-reported date of first reported sign/symptom from the following list:\n\n  * subjective fever or feeling feverish\n  * cough\n  * shortness of breath or difficulty breathing at rest or with activity\n  * sore throat\n  * body pain or muscle pain/aches\n  * fatigue\n  * headache\n  * chills\n  * nasal obstruction or congestion\n  * nasal discharge\n  * loss of taste or smell\n  * nausea or vomiting\n  * diarrhea\n  * temperature \\> 38°C (100.4°F)\n* One or more of the following signs/symptoms within 24 hours of participating in the study:\n\n  * subjective fever or feeling feverish\n  * cough\n  * shortness of breath or difficulty breathing at rest or with activity\n  * sore throat\n  * body pain or muscle pain/aches\n  * fatigue\n  * headache\n  * chills\n  * nasal obstruction or congestion\n  * nasal discharge\n  * loss of taste or smell\n  * nausea or vomiting\n  * diarrhea\n  * temperature \\> 38°C (100.4°F)\n* Oxygen levels of ≥92% obtained at rest (adjusted as needed for altitude) by study staff within 24 hours of study entry. For a potential participant who regularly receives chronic supplementary oxygen for an underlying lung condition, their oxygen saturation should be measured while on their standard home oxygen supplementation level.\n* Participant must agree not to participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days after the start of the study, whichever occurs first.\n* Meet the protocol definition of being at \"higher\" risk of progression to hospitalization or death (BRII-196/BRII-198).\n* In Phase III, meeting the protocol definition of being at \"higher\" risk of progression to hospitalization or death (SNG001, SAB-185, BMS 986414+BMS 986413)\n* For participants of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA-waived test. Note: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method (BRII-196/BRII-198. AZD7442 \\[IV\\], AZD7442 \\[IM\\], SNG001, Camostat, SAB-185, BMS 986414+BMS 986413).\n* Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are strongly advised to inform their non-pregnant sexual partners of reproductive potential to use effective contraceptives for 24 weeks after investigational product is administered. Participants with pregnant partners should use condoms during vaginal intercourse through 24 weeks after investigational agent administration. Participants should refrain from sperm donation for 24 weeks after investigational agent administration (BRII-196/BRII-198, AZD7442 \\[IV\\], AZD7442 \\[IM\\], SAB-185).\n* Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives for 30 days after investigational agent administration. They are also strongly advised to inform their non-pregnant sexual partners of reproductive potential to sue effective contraceptives for 30 days after investigational agent is administered to the participant. Participants with pregnant partners should use condoms during vaginal intercourse through 30 days after last dose of investigational agent administration. Participants should refrain from sperm donation for 30 days after investigational agent administration (SNG001).\n* Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-regnant sexual partners of reproductive potential to use effective contraceptives from study entry through 90 days after study treatment. Participants with pregnant partners should use condoms during vaginal intercourse from study entry through 90 days after the last dose of the study treatment. Participants should refrain from sperm donation from study entry through 90 days after the last dose of study treatment (Camostat).\n* If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 24 weeks after investigational agent is administered. This would include oral contraceptives, implanted contraceptives, implanted contraceptives, intrauterine devices, and barrier methods.\n* If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use highly effective contraception for 24 weeks after investigational agent is administered (AZD7442 \\[IV\\], AZD7442 \\[IM\\], SAB-185).\n* If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 30 days after investigational agent is administered (SNG001).\n* If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 90 days after the last dose of treatment (Camostat).\n* If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use highly effective contraception for at least 48 weeks after the investigational agent is administered (BMS 986414+BMS 986413).\n\nExclusion Criteria:\n\n* History of or current hospitalization for COVID-19.\n* For the current SARS-CoV-2 infection, any positive SARS-CoV-2 nucleic acid or antigen tests from any respiratory tract specimen collected \\> 240 hours prior to study entry.\n* Current need for hospitalization or immediate medical attention.\n* Use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of COVID-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study.\n* Receipt of convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 treatment or prophylaxis at any time prior to study entry.\n* Receipt of other investigational treatments for SARS-CoV-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases or COVID-19 vaccines).\n* Known allergy/sensitivity or hypersensitivity to study drug or placebo.\n* Any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study.\n* Currently pregnant or breastfeeding (BRII-196/BRII-198, AZD7442 \\[IV\\], AZD7442 \\[IM\\], SNG001, Camostat, SAB-185, BMS 986414+BMS 986413).\n* In phase II, meeting the protocol definition of being at \"higher\" risk of progression to hospitalization or death (AZD7442 \\[IV\\], AZD7442 \\[IM\\], SNG001, Camostat, SAB-185, BMS 986414+BMS 986413).\n* Inflammatory skin conditions that compromise the safety of intramuscular (IM) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (AZD7442 \\[IM\\]).\n* Inflammatory skin conditions that compromise the safety of subcutaneous (SC) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (BMS 986414+BMS 986413).\n* History of coagulopathy which, in the opinion of the investigator, would preclude IM injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (AZD7442 \\[IM\\]).\n* Use of or need for chronic supplemental oxygen (SNG001).\n* Known severe liver disease prior to enrollment (defined as ALT or AST \\> 5 times upper limit of normal or end stage liver disease with Child-Pugh Class C or Child-Pugh-Turcotte score ≥ 10) (Camostat).\n* Known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (eGFR) \\<30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (Camostat)\n\nOther investigational drug protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"COVID-19 Symptom Duration (Phase 2)","description":"Bamlanivimab arms:\n\nSymptom duration=max. duration (days) across targeted symptoms including: feeling feverish, cough, shortness of breath/difficulty breathing at rest/with activity, sore throat, body pain/muscle pain/aches, fatigue, headache, chills, nasal obstruction/congestion, nasal discharge, nausea, vomiting, and diarrhea. Subjects who die on/before day 28 assigned symptom duration 29 days.\n\nNo scale. Min. value: 0 Days, Max. Value 29 Days. Higher value=worse health condition.\n\nNon-Bamlanivimab arms:\n\n13 symptoms (as for Bamlanivimab) scored daily as absent (score 0), mild (score 1), moderate (score 2) or severe (score 3). Symptom duration=time (days) from Day 0 (pre-treatment) to first of two consecutive days when all symptoms scored moderate/severe at Day 0 (pre-treatment) are scored mild/absent, AND all symptoms scored mild/absent at Day 0 (pre-treatment) are scored absent.\n\nNo scale. Min. value: 0 Days, Max. Value 26 Days. Higher value=worse health condition.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"18.5","spread":null},{"groupId":"OG002","value":"24.0","spread":null},{"groupId":"OG003","value":"20.5","spread":null},{"groupId":"OG004","value":"11.00","spread":null},{"groupId":"OG005","value":"10.00","spread":null},{"groupId":"OG006","value":"8.00","spread":null},{"groupId":"OG007","value":"10.00","spread":null},{"groupId":"OG008","value":"13.0","spread":null},{"groupId":"OG009","value":"9.0","spread":null},{"groupId":"OG010","value":"9","spread":null},{"groupId":"OG011","value":"9","spread":null},{"groupId":"OG012","value":"11.0","spread":null},{"groupId":"OG013","value":"10.0","spread":null},{"groupId":"OG014","value":"8.0","spread":null},{"groupId":"OG015","value":"10.0","spread":null},{"groupId":"OG016","value":"8.0","spread":null},{"groupId":"OG017","value":"10.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Quantification of SARS-CoV-2 RNA (Phase 2)","description":"Bamlanivimab Agent arms:\n\nMeasured as Detected or Undetected from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Detection is 1.4 (log 10 copies/ml).\n\nNon-Bamlanivimab Agent arms:\n\nMeasured as below Lower Limit of Quantification (LLoQ) or at/above LLoQ from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Quantification is 2 (log 10 copies/ml).\n\nSNG001 and SNG001 Pooled Placebo arm each exclude 6 participants, due to unsuitable sample specimen conditions.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"25","spread":null},{"groupId":"OG005","value":"23","spread":null},{"groupId":"OG006","value":"26","spread":null},{"groupId":"OG007","value":"36","spread":null},{"groupId":"OG008","value":"26","spread":null},{"groupId":"OG009","value":"37","spread":null},{"groupId":"OG010","value":"28","spread":null},{"groupId":"OG011","value":"32","spread":null},{"groupId":"OG012","value":"39","spread":null},{"groupId":"OG013","value":"34","spread":null},{"groupId":"OG014","value":"35","spread":null},{"groupId":"OG015","value":"32","spread":null},{"groupId":"OG016","value":"42","spread":null},{"groupId":"OG017","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"24","spread":null},{"groupId":"OG005","value":"21","spread":null},{"groupId":"OG006","value":"57","spread":null},{"groupId":"OG007","value":"52","spread":null},{"groupId":"OG008","value":"67","spread":null},{"groupId":"OG009","value":"57","spread":null},{"groupId":"OG010","value":"60","spread":null},{"groupId":"OG011","value":"48","spread":null},{"groupId":"OG012","value":"44","spread":null},{"groupId":"OG013","value":"55","spread":null},{"groupId":"OG014","value":"56","spread":null},{"groupId":"OG015","value":"56","spread":null},{"groupId":"OG016","value":"46","spread":null},{"groupId":"OG017","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"7","spread":null},{"groupId":"OG006","value":"20","spread":null},{"groupId":"OG007","value":"23","spread":null},{"groupId":"OG008","value":"17","spread":null},{"groupId":"OG009","value":"16","spread":null},{"groupId":"OG010","value":"18","spread":null},{"groupId":"OG011","value":"25","spread":null},{"groupId":"OG012","value":"23","spread":null},{"groupId":"OG013","value":"14","spread":null},{"groupId":"OG014","value":"16","spread":null},{"groupId":"OG015","value":"14","spread":null},{"groupId":"OG016","value":"17","spread":null},{"groupId":"OG017","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Quantification of SARS-CoV-2 RNA (Phase 2)","description":"Bamlanivimab Agent arms:\n\nMeasured as Detected or Undetected from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Detection is 1.4 (log 10 copies/ml).\n\nNon-Bamlanivimab Agent arms:\n\nMeasured as below Lower Limit of Quantification (LLoQ) or at/above LLoQ from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Quantification is 2 (log 10 copies/ml).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"17","spread":null},{"groupId":"OG004","value":"35","spread":null},{"groupId":"OG005","value":"31","spread":null},{"groupId":"OG006","value":"66","spread":null},{"groupId":"OG007","value":"59","spread":null},{"groupId":"OG008","value":"60","spread":null},{"groupId":"OG009","value":"62","spread":null},{"groupId":"OG010","value":"53","spread":null},{"groupId":"OG011","value":"60","spread":null},{"groupId":"OG012","value":"63","spread":null},{"groupId":"OG013","value":"54","spread":null},{"groupId":"OG014","value":"69","spread":null},{"groupId":"OG015","value":"52","spread":null},{"groupId":"OG016","value":"71","spread":null},{"groupId":"OG017","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"89","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"13","spread":null},{"groupId":"OG006","value":"17","spread":null},{"groupId":"OG007","value":"34","spread":null},{"groupId":"OG008","value":"33","spread":null},{"groupId":"OG009","value":"32","spread":null},{"groupId":"OG010","value":"31","spread":null},{"groupId":"OG011","value":"29","spread":null},{"groupId":"OG012","value":"28","spread":null},{"groupId":"OG013","value":"29","spread":null},{"groupId":"OG014","value":"24","spread":null},{"groupId":"OG015","value":"30","spread":null},{"groupId":"OG016","value":"19","spread":null},{"groupId":"OG017","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"8","spread":null},{"groupId":"OG005","value":"7","spread":null},{"groupId":"OG006","value":"20","spread":null},{"groupId":"OG007","value":"18","spread":null},{"groupId":"OG008","value":"17","spread":null},{"groupId":"OG009","value":"16","spread":null},{"groupId":"OG010","value":"22","spread":null},{"groupId":"OG011","value":"16","spread":null},{"groupId":"OG012","value":"15","spread":null},{"groupId":"OG013","value":"20","spread":null},{"groupId":"OG014","value":"14","spread":null},{"groupId":"OG015","value":"20","spread":null},{"groupId":"OG016","value":"15","spread":null},{"groupId":"OG017","value":"19","spread":null}]}]}]},{"type":"PRIMARY","title":"Quantification of SARS-CoV-2 RNA (Phase 2)","description":"Bamlanivimab Agent arms:\n\nMeasured as Detected or Undetected from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Detection is 1.4 (log 10 copies/ml).\n\nNon-Bamlanivimab Agent arms:\n\nMeasured as below Lower Limit of Quantification (LLoQ) or at/above LLoQ from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Quantification is 2 (log 10 copies/ml).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"33","spread":null},{"groupId":"OG004","value":"44","spread":null},{"groupId":"OG005","value":"42","spread":null},{"groupId":"OG006","value":"70","spread":null},{"groupId":"OG007","value":"81","spread":null},{"groupId":"OG008","value":"85","spread":null},{"groupId":"OG009","value":"83","spread":null},{"groupId":"OG010","value":"73","spread":null},{"groupId":"OG011","value":"75","spread":null},{"groupId":"OG012","value":"81","spread":null},{"groupId":"OG013","value":"81","spread":null},{"groupId":"OG014","value":"85","spread":null},{"groupId":"OG015","value":"78","spread":null},{"groupId":"OG016","value":"82","spread":null},{"groupId":"OG017","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"69","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"12","spread":null},{"groupId":"OG007","value":"10","spread":null},{"groupId":"OG008","value":"9","spread":null},{"groupId":"OG009","value":"8","spread":null},{"groupId":"OG010","value":"11","spread":null},{"groupId":"OG011","value":"10","spread":null},{"groupId":"OG012","value":"9","spread":null},{"groupId":"OG013","value":"5","spread":null},{"groupId":"OG014","value":"6","spread":null},{"groupId":"OG015","value":"6","spread":null},{"groupId":"OG016","value":"8","spread":null},{"groupId":"OG017","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"21","spread":null},{"groupId":"OG007","value":"20","spread":null},{"groupId":"OG008","value":"16","spread":null},{"groupId":"OG009","value":"19","spread":null},{"groupId":"OG010","value":"22","spread":null},{"groupId":"OG011","value":"20","spread":null},{"groupId":"OG012","value":"16","spread":null},{"groupId":"OG013","value":"17","spread":null},{"groupId":"OG014","value":"16","spread":null},{"groupId":"OG015","value":"18","spread":null},{"groupId":"OG016","value":"15","spread":null},{"groupId":"OG017","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 2)","description":"AE Severity: Adverse event Severity grading followed Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at:\n\nhttps://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables.\n\n* Grade 1 indicates a mild event\n* Grade 2 indicates a moderate event\n* Grade 3 indicates a severe event\n* Grade 4 indicates a potentially life-threatening event\n* Grade 5 indicates death","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"10","spread":null},{"groupId":"OG007","value":"8","spread":null},{"groupId":"OG008","value":"4","spread":null},{"groupId":"OG009","value":"9","spread":null},{"groupId":"OG010","value":"10","spread":null},{"groupId":"OG011","value":"8","spread":null},{"groupId":"OG012","value":"5","spread":null},{"groupId":"OG013","value":"11","spread":null},{"groupId":"OG014","value":"10","spread":null},{"groupId":"OG015","value":"10","spread":null},{"groupId":"OG016","value":"6","spread":null},{"groupId":"OG017","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phase 3)","description":"Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19. An event is defined as first occurrence of hospitalization/death (i.e. if subject has multiple hospitalizations, only the first hospitalization is counted as an event). Therefore, an event can only occur once for a subject. Results are presented as number of events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"44","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 3)","description":"AE Severity: Adverse event Severity grading followed Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at:\n\nhttps://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables.\n\n* Grade 1 indicates a mild event\n* Grade 2 indicates a moderate event\n* Grade 3 indicates a severe event\n* Grade 4 indicates a potentially life-threatening event\n* Grade 5 indicates death","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"67","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"16","spread":null},{"groupId":"OG005","value":"17","spread":null},{"groupId":"OG006","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID-19 Symptom Duration (Phase 3)","description":"Bamlanivimab arm:\n\nSymptom duration=max. duration (days) across targeted symptoms including: feeling feverish, cough, shortness of breath/difficulty breathing at rest/with activity, sore throat, body pain/muscle pain/aches, fatigue, headache, chills, nasal obstruction/congestion, nasal discharge, nausea, vomiting, and diarrhea. Subjects who die on/before day 28 assigned symptom duration 29 days.\n\nNo scale. Min. value: 0 Days, Max. Value 29 Days. Higher value=worse health condition.\n\nNon-Bamlanivimab arms:\n\n13 symptoms (as for Bamlanivimab) scored daily as absent (score 0), mild (score 1), moderate (score 2) or severe (score 3). Symptom duration=time (days) from Day 0 (pre-treatment) to first of two consecutive days when all symptoms scored moderate/severe at Day 0 (pre-treatment) are scored mild/absent, AND all symptoms scored mild/absent at Day 0 (pre-treatment) are scored absent.\n\nNo scale. Min. value: 0 Days, Max. Value 26 Days. Higher value=worse health condition.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"11.0","spread":null},{"groupId":"OG002","value":"11.0","spread":null},{"groupId":"OG003","value":"11.0","spread":null},{"groupId":"OG004","value":"13.00","spread":null},{"groupId":"OG005","value":"11.0","spread":null},{"groupId":"OG006","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Quantification of SARS-CoV-2 RNA (Phase 3)","description":"Measured as Detected or Undetected from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Detection is 1.4 (log 10 copies/ml).\n\nNon-Bamlanivimab Agent arms:\n\nMeasured as below Lower Limit of Quantification (LLoQ) or at/above LLoQ from staff-collected NP (nasopharyngeal) swabs. Lower Limit of Quantification is 2 (log 10 copies/ml).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"47","spread":null},{"groupId":"OG004","value":"47","spread":null},{"groupId":"OG005","value":"57","spread":null},{"groupId":"OG006","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"119","spread":null},{"groupId":"OG004","value":"111","spread":null},{"groupId":"OG005","value":"56","spread":null},{"groupId":"OG006","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"32","spread":null},{"groupId":"OG004","value":"36","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death From Any Cause or Hospitalization Due to Any Cause (Phase 2)","description":"Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19. An event is defined as first occurrence of hospitalization/death (i.e. if subject has multiple hospitalizations, only the first hospitalization is counted as an event). Therefore, an event can only occur once for a subject. Results are presented as number of events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"4","spread":null},{"groupId":"OG007","value":"7","spread":null},{"groupId":"OG008","value":"1","spread":null},{"groupId":"OG009","value":"7","spread":null},{"groupId":"OG010","value":"6","spread":null},{"groupId":"OG011","value":"5","spread":null},{"groupId":"OG012","value":"2","spread":null},{"groupId":"OG013","value":"4","spread":null},{"groupId":"OG014","value":"5","spread":null},{"groupId":"OG015","value":"4","spread":null},{"groupId":"OG016","value":"6","spread":null},{"groupId":"OG017","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death From Any Cause, or Hospitalization Due to Any Cause Related to COVID-19 (Phase 3)","description":"Hospitalizations due to any cause deemed unrelated to COVID-19 are excluded. Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19. An event is defined as first occurrence of hospitalization/death (i.e. if subject has multiple hospitalizations, only the first hospitalization is counted as an event). Therefore, an event can only occur once for a subject. Results are presented as number of events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Level of SARS-CoV-2 RNA From NP Swabs (Phase 2)","description":"Measured from staff-collected NP swabs","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.357","spread":"0.8371"},{"groupId":"OG001","value":"1.201","spread":"0.8123"},{"groupId":"OG002","value":"1.669","spread":"1.0883"},{"groupId":"OG003","value":"1.552","spread":"0.7373"},{"groupId":"OG004","value":"1.09","spread":"0.565"},{"groupId":"OG005","value":"1.15","spread":"0.655"},{"groupId":"OG006","value":"1.20","spread":"0.857"},{"groupId":"OG007","value":"1.32","spread":"0.740"},{"groupId":"OG008","value":"1.051","spread":"0.6425"},{"groupId":"OG009","value":"1.114","spread":"0.6786"},{"groupId":"OG010","value":"1.315","spread":"0.7722"},{"groupId":"OG011","value":"1.316","spread":"0.7152"},{"groupId":"OG012","value":"1.095","spread":"0.8025"},{"groupId":"OG013","value":"0.953","spread":"0.5247"},{"groupId":"OG014","value":"0.950","spread":"0.6005"},{"groupId":"OG015","value":"0.976","spread":"0.5428"},{"groupId":"OG016","value":"1.1","spread":"NA"},{"groupId":"OG017","value":"1.0","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Level of SARS-CoV-2 RNA From NP Swabs (Phase 3)","description":"Measured from staff-collected NP swabs","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"2.899","spread":"1.5822"},{"groupId":"OG002","value":"3.122","spread":"2.0459"},{"groupId":"OG003","value":"3.960","spread":"2.1722"},{"groupId":"OG004","value":"3.857","spread":"2.2445"},{"groupId":"OG005","value":"2.745","spread":"2.1912"},{"groupId":"OG006","value":"2.935","spread":"2.0670"}]}]}]},{"type":"SECONDARY","title":"Duration of Targeted Clinical COVID-19 Symptoms (Phases 2 and 3)","description":"Duration defined as the number of days from start of investigational agent to the first of four consecutive days when all symptoms scored as absent. Targeted symptoms are: Feeling feverish; cough, shortness of breath or difficulty breathing; sore throat; body pain or muscle pain/aches; fatigue (low energy); headache, chills, nasal obstruction or congestion (stuffy nose); nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG005","value":"19.0","spread":null},{"groupId":"OG006","value":"23.0","spread":null},{"groupId":"OG007","value":"16.00","spread":null},{"groupId":"OG008","value":"17.00","spread":null},{"groupId":"OG009","value":"16.00","spread":null},{"groupId":"OG010","value":"14.00","spread":null},{"groupId":"OG013","value":"16.0","spread":null},{"groupId":"OG014","value":"24.0","spread":null},{"groupId":"OG017","value":"8.0","spread":null},{"groupId":"OG018","value":"10.0","spread":null},{"groupId":"OG019","value":"18.0","spread":null},{"groupId":"OG020","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID-19 Symptom Severity Ranking (Phases 2 and 3)","description":"Symptoms scored daily as absent (score 0), mild (score 1), moderate (score 2) or severe (score 3). Symptoms: feeling feverish, cough, shortness of breath/difficulty breathing at rest/with activity, sore throat, body pain/muscle pain/aches, fatigue, headache, chills, nasal obstruction/congestion, nasal discharge, nausea, vomiting, and diarrhea. Subjects alive and never hospitalized through Day 28: Symptom Severity Ranking=subject-specific AUC (area under curve) joining daily total symptom score associated with COVID-19 disease, over time (through Day 28, counting Day 0 as first day), calculated by trapezoidal rule and rescaled for time by dividing by the total number of trapezoids. Subjects who died within Day 28: Assigned severity score 42; Subjects alive but remaining hospitalized at Day 28: Assigned severity score 41; Subjects alive but no longer hospitalized at Day 28: Assigned severity score 40.\n\nCalculated Severity Score=scale of 0 to 42. Higher value=worse health condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4940","spread":"7.83544"},{"groupId":"OG001","value":"5.6939","spread":"11.09572"},{"groupId":"OG002","value":"4.1395","spread":"7.35047"},{"groupId":"OG003","value":"4.0378","spread":"7.37122"},{"groupId":"OG004","value":"4.4001","spread":"7.42311"},{"groupId":"OG005","value":"4.1213","spread":"6.12801"},{"groupId":"OG006","value":"7.8505","spread":"12.16647"},{"groupId":"OG007","value":"3.5","spread":"3.35"},{"groupId":"OG008","value":"5.8","spread":"10.44"},{"groupId":"OG009","value":"4.6","spread":"8.16"},{"groupId":"OG010","value":"5.5","spread":"9.74"},{"groupId":"OG011","value":"3.6360","spread":"4.67064"},{"groupId":"OG012","value":"5.5345","spread":"9.68874"},{"groupId":"OG013","value":"5.3314","spread":"9.41155"},{"groupId":"OG014","value":"5.1306","spread":"8.69588"},{"groupId":"OG015","value":"4.1020","spread":"6.33252"},{"groupId":"OG016","value":"4.5759","spread":"7.82761"},{"groupId":"OG017","value":"4.7658","spread":"6.71588"},{"groupId":"OG018","value":"5.0532","spread":"6.03326"},{"groupId":"OG019","value":"5.6263","spread":"8.89389"},{"groupId":"OG020","value":"4.5862","spread":"6.27948"},{"groupId":"OG021","value":"4.6631","spread":"8.38511"},{"groupId":"OG022","value":"4.5728","spread":"7.87041"},{"groupId":"OG023","value":"4.6","spread":"7.51"},{"groupId":"OG024","value":"4.2","spread":"6.88"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With ≥1 Worsening Symptom of COVID-19 (Phases 2 and 3)","description":"Progression of one or more COVID-19-associated symptoms to a worse status than recorded in study diary at study entry, prior to start of investigational product or placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"102","spread":null},{"groupId":"OG003","value":"105","spread":null},{"groupId":"OG004","value":"876","spread":null},{"groupId":"OG005","value":"323","spread":null},{"groupId":"OG006","value":"321","spread":null},{"groupId":"OG007","value":"42","spread":null},{"groupId":"OG008","value":"43","spread":null},{"groupId":"OG009","value":"87","spread":null},{"groupId":"OG010","value":"96","spread":null},{"groupId":"OG011","value":"86","spread":null},{"groupId":"OG012","value":"92","spread":null},{"groupId":"OG013","value":"82","spread":null},{"groupId":"OG014","value":"92","spread":null},{"groupId":"OG015","value":"81","spread":null},{"groupId":"OG016","value":"81","spread":null},{"groupId":"OG017","value":"102","spread":null},{"groupId":"OG018","value":"119","spread":null},{"groupId":"OG019","value":"83","spread":null},{"groupId":"OG020","value":"79","spread":null},{"groupId":"OG021","value":"70","spread":null},{"groupId":"OG022","value":"86","spread":null},{"groupId":"OG023","value":"160","spread":null},{"groupId":"OG024","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Self-reported Return to Usual Health (a) (Phases 2 and 3)","description":"Defined as the number of days from start of investigational treatment until the first of two consecutive days that a participant reported return to usual (pre-COVID-19) health as recorded in a participant's study diary.\n\nNot analyzed for Bamlanivimab Phase 2 and Phase 3 arms.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG005","value":"16.0","spread":null},{"groupId":"OG006","value":"22.0","spread":null},{"groupId":"OG007","value":"11.00","spread":null},{"groupId":"OG008","value":"15.00","spread":null},{"groupId":"OG009","value":"14.00","spread":null},{"groupId":"OG010","value":"13.00","spread":null},{"groupId":"OG011","value":"19.0","spread":null},{"groupId":"OG012","value":"17.0","spread":null},{"groupId":"OG013","value":"12.0","spread":null},{"groupId":"OG014","value":"14.0","spread":null},{"groupId":"OG015","value":"15.0","spread":null},{"groupId":"OG016","value":"17.0","spread":null},{"groupId":"OG017","value":"11.0","spread":null},{"groupId":"OG018","value":"12.0","spread":null},{"groupId":"OG019","value":"12.0","spread":null},{"groupId":"OG020","value":"17.0","spread":null},{"groupId":"OG021","value":"12.0","spread":null},{"groupId":"OG022","value":"17.0","spread":null},{"groupId":"OG023","value":"15.0","spread":null},{"groupId":"OG024","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phases 2 and 3)","description":"Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19. An event is defined as first occurrence of hospitalization/death (i.e. if subject has multiple hospitalizations, only the first hospitalization is counted as an event). Therefore, an event can only occur once for a subject. Results are presented as number of events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"44","spread":null},{"groupId":"OG005","value":"13","spread":null},{"groupId":"OG006","value":"46","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"5","spread":null},{"groupId":"OG009","value":"5","spread":null},{"groupId":"OG010","value":"8","spread":null},{"groupId":"OG011","value":"2","spread":null},{"groupId":"OG012","value":"7","spread":null},{"groupId":"OG013","value":"6","spread":null},{"groupId":"OG014","value":"6","spread":null},{"groupId":"OG015","value":"3","spread":null},{"groupId":"OG016","value":"5","spread":null},{"groupId":"OG017","value":"7","spread":null},{"groupId":"OG018","value":"8","spread":null},{"groupId":"OG019","value":"5","spread":null},{"groupId":"OG020","value":"5","spread":null},{"groupId":"OG021","value":"7","spread":null},{"groupId":"OG022","value":"5","spread":null},{"groupId":"OG023","value":"6","spread":null},{"groupId":"OG024","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phases 2 and 3)","description":"Not applicable to Bamlanivimab arms as these were only 24 week-long studies. Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19. An event is defined as first occurrence of hospitalization/death (i.e. if subject has multiple hospitalizations, only the first hospitalization is counted as an event). Therefore, an event can only occur once for a subject. Results are presented as number of events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG005","value":"23","spread":null},{"groupId":"OG006","value":"59","spread":null},{"groupId":"OG007","value":"3","spread":null},{"groupId":"OG008","value":"5","spread":null},{"groupId":"OG009","value":"7","spread":null},{"groupId":"OG010","value":"8","spread":null},{"groupId":"OG011","value":"2","spread":null},{"groupId":"OG012","value":"7","spread":null},{"groupId":"OG013","value":"9","spread":null},{"groupId":"OG014","value":"6","spread":null},{"groupId":"OG015","value":"4","spread":null},{"groupId":"OG016","value":"5","spread":null},{"groupId":"OG017","value":"11","spread":null},{"groupId":"OG018","value":"9","spread":null},{"groupId":"OG019","value":"5","spread":null},{"groupId":"OG020","value":"5","spread":null},{"groupId":"OG021","value":"7","spread":null},{"groupId":"OG022","value":"5","spread":null},{"groupId":"OG023","value":"10","spread":null},{"groupId":"OG024","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Oxygen Saturation Level (Phases 2 and 3)","description":"Measured by pulse oximeter and categorized as \\<96% versus ≥96%. Analysis not performed for Bamlanivimab arms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG005","value":"94","spread":null},{"groupId":"OG006","value":"94","spread":null},{"groupId":"OG007","value":"45","spread":null},{"groupId":"OG008","value":"42","spread":null},{"groupId":"OG009","value":"89","spread":null},{"groupId":"OG010","value":"90","spread":null},{"groupId":"OG011","value":"99","spread":null},{"groupId":"OG012","value":"95","spread":null},{"groupId":"OG013","value":"87","spread":null},{"groupId":"OG014","value":"87","spread":null},{"groupId":"OG015","value":"95","spread":null},{"groupId":"OG016","value":"90","spread":null},{"groupId":"OG017","value":"97","spread":null},{"groupId":"OG018","value":"111","spread":null},{"groupId":"OG019","value":"96","spread":null},{"groupId":"OG020","value":"89","spread":null},{"groupId":"OG021","value":"88","spread":null},{"groupId":"OG022","value":"88","spread":null},{"groupId":"OG023","value":"177","spread":null},{"groupId":"OG024","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"2","spread":null},{"groupId":"OG009","value":"2","spread":null},{"groupId":"OG010","value":"3","spread":null},{"groupId":"OG011","value":"1","spread":null},{"groupId":"OG012","value":"2","spread":null},{"groupId":"OG013","value":"3","spread":null},{"groupId":"OG014","value":"4","spread":null},{"groupId":"OG015","value":"3","spread":null},{"groupId":"OG016","value":"2","spread":null},{"groupId":"OG017","value":"9","spread":null},{"groupId":"OG018","value":"8","spread":null},{"groupId":"OG019","value":"2","spread":null},{"groupId":"OG020","value":"2","spread":null},{"groupId":"OG021","value":"1","spread":null},{"groupId":"OG022","value":"2","spread":null},{"groupId":"OG023","value":"5","spread":null},{"groupId":"OG024","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"7","spread":null},{"groupId":"OG007","value":"10","spread":null},{"groupId":"OG008","value":"7","spread":null},{"groupId":"OG009","value":"12","spread":null},{"groupId":"OG010","value":"18","spread":null},{"groupId":"OG011","value":"10","spread":null},{"groupId":"OG012","value":"13","spread":null},{"groupId":"OG013","value":"16","spread":null},{"groupId":"OG014","value":"13","spread":null},{"groupId":"OG015","value":"6","spread":null},{"groupId":"OG016","value":"11","spread":null},{"groupId":"OG017","value":"15","spread":null},{"groupId":"OG018","value":"15","spread":null},{"groupId":"OG019","value":"9","spread":null},{"groupId":"OG020","value":"11","spread":null},{"groupId":"OG021","value":"16","spread":null},{"groupId":"OG022","value":"17","spread":null},{"groupId":"OG023","value":"16","spread":null},{"groupId":"OG024","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"AUC of SARS-CoV-2 RNA From Site-collected NP Swabs (Phase 2)","description":"Measured by area under the curve (AUC) and above assay lower limit of quantification of quantitative SARS-CoV-2 RNA over time.\n\nNot analyzed for Bamlanivimab arms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG004","value":"9.2","spread":"10.127"},{"groupId":"OG005","value":"11.7","spread":"16.505"},{"groupId":"OG006","value":"12.5","spread":"11.497"},{"groupId":"OG007","value":"14.0","spread":"15.134"},{"groupId":"OG008","value":"13.7450","spread":"11.03930"},{"groupId":"OG009","value":"13.1472","spread":"13.34285"},{"groupId":"OG010","value":"15.2756","spread":"12.81071"},{"groupId":"OG011","value":"13.9833","spread":"13.85182"},{"groupId":"OG012","value":"11.2405","spread":"12.06870"},{"groupId":"OG013","value":"12.8663","spread":"14.03668"},{"groupId":"OG014","value":"11.6766","spread":"11.40875"},{"groupId":"OG015","value":"13.6064","spread":"14.17869"},{"groupId":"OG016","value":"9.5","spread":"11.20"},{"groupId":"OG017","value":"10.9","spread":"11.87"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With New Adverse Event (AE) ≥ Grade 2 (Phases 2 and 3)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"30","spread":null},{"groupId":"OG005","value":"29","spread":null},{"groupId":"OG006","value":"45","spread":null},{"groupId":"OG007","value":"20","spread":null},{"groupId":"OG008","value":"14","spread":null},{"groupId":"OG009","value":"30","spread":null},{"groupId":"OG010","value":"25","spread":null},{"groupId":"OG011","value":"24","spread":null},{"groupId":"OG012","value":"31","spread":null},{"groupId":"OG013","value":"29","spread":null},{"groupId":"OG014","value":"25","spread":null},{"groupId":"OG015","value":"20","spread":null},{"groupId":"OG016","value":"26","spread":null},{"groupId":"OG017","value":"40","spread":null},{"groupId":"OG018","value":"45","spread":null},{"groupId":"OG019","value":"25","spread":null},{"groupId":"OG020","value":"23","spread":null},{"groupId":"OG021","value":"22","spread":null},{"groupId":"OG022","value":"28","spread":null},{"groupId":"OG023","value":"58","spread":null},{"groupId":"OG024","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With New Adverse Event (AE) ≥ Grade 2 (Phases 2 and 3)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG005","value":"45","spread":null},{"groupId":"OG006","value":"50","spread":null},{"groupId":"OG007","value":"23","spread":null},{"groupId":"OG008","value":"17","spread":null},{"groupId":"OG009","value":"38","spread":null},{"groupId":"OG010","value":"33","spread":null},{"groupId":"OG011","value":"34","spread":null},{"groupId":"OG012","value":"41","spread":null},{"groupId":"OG013","value":"32","spread":null},{"groupId":"OG014","value":"32","spread":null},{"groupId":"OG015","value":"27","spread":null},{"groupId":"OG016","value":"32","spread":null},{"groupId":"OG017","value":"46","spread":null},{"groupId":"OG018","value":"60","spread":null},{"groupId":"OG019","value":"31","spread":null},{"groupId":"OG020","value":"30","spread":null},{"groupId":"OG021","value":"76","spread":null},{"groupId":"OG022","value":"74","spread":null},{"groupId":"OG023","value":"72","spread":null},{"groupId":"OG024","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With New Adverse Event (AE) ≥ Grade 3 (Phases 2 and 3)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"37","spread":null},{"groupId":"OG006","value":"74","spread":null},{"groupId":"OG011","value":"5","spread":null},{"groupId":"OG012","value":"11","spread":null},{"groupId":"OG013","value":"12","spread":null},{"groupId":"OG014","value":"12","spread":null},{"groupId":"OG015","value":"8","spread":null},{"groupId":"OG016","value":"13","spread":null},{"groupId":"OG017","value":"17","spread":null},{"groupId":"OG018","value":"27","spread":null},{"groupId":"OG019","value":"11","spread":null},{"groupId":"OG020","value":"12","spread":null},{"groupId":"OG023","value":"30","spread":null},{"groupId":"OG024","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Self-reported Return to Usual Health (b) (Phases 2 and 3)","description":"Defined as the number of days from start of investigational treatment until the first of four consecutive days that a participant reported return to usual (pre-COVID-19) health as recorded in a participant's study diary.\n\nNot collected for Bamlanivimab Phase 2 and Phase 3 arms.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG007","value":"13.00","spread":null},{"groupId":"OG008","value":"17.00","spread":null},{"groupId":"OG009","value":"15.00","spread":null},{"groupId":"OG010","value":"15.00","spread":null},{"groupId":"OG013","value":"14.0","spread":null},{"groupId":"OG014","value":"15.0","spread":null},{"groupId":"OG017","value":"13.0","spread":null},{"groupId":"OG018","value":"17.0","spread":null},{"groupId":"OG019","value":"17.0","spread":null},{"groupId":"OG020","value":"15.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Headache","Blood glucose increased","COVID-19","Fatigue","Diarrhoea"]}}}